Traitements3programmes
Essais1liés
Publications0liées
SourceDBlocale

Traitements

3
MoléculeIndication / populationPhaseObjectifPaysRésultat
Empirical therapy groupThis is a prospective randomised clinical trial performed in a single center at Hospital Universiti Sains Malaysia (USM), Kelantan, Malaysia. Participants will be randomly allocated into either the empirical group or guided group for 8 weeks.The effectiveness in relieving chest pain (frequency and severity) will assessed after 2 weeks and 8 weeks of therapy with Gastroesophageal Reflux Disease Questionnaire (GERDQ) and Quality of Life Reflux and Dyspepsia (QOLRAD) questionnaire, and visual analogue scale (VAS) (score 1-10). SEP Phase 2/3 Traitement symptomatique Malaysia À vérifier
Guided therapy groupThis is a prospective randomised clinical trial performed in a single center at Hospital Universiti Sains Malaysia (USM), Kelantan, Malaysia. Participants will be randomly allocated into either the empirical group or guided group for 8 weeks.The effectiveness in relieving chest pain (frequency and severity) will assessed after 2 weeks and 8 weeks of therapy with Gastroesophageal Reflux Disease Questionnaire (GERDQ) and Quality of Life Reflux and Dyspepsia (QOLRAD) questionnaire, and visual analogue scale (VAS) (score 1-10). SEP Phase 2/3 Traitement symptomatique Malaysia À vérifier
Empirical therapy groupThis is a prospective randomised clinical trial performed in a single center at Hospital Universiti Sains Malaysia (USM), Kelantan, Malaysia. Participants will be randomly allocated into either the empirical group or guided group for 8 weeks.The effectiveness in relieving chest pain (frequency and severity) will assessed after 2 weeks and 8 weeks of therapy with Gastroesophageal Reflux Disease Questionnaire (GERDQ) and Quality of Life Reflux and Dyspepsia (QOLRAD) questionnaire, and visual analogue scale (VAS) (score 1-10). SEP Phase 2/3 Traitement symptomatique Malaysia À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Empirical therapy group SEP Phase 2/3 NCT03319121 The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain COMPLETED

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.